Program
secukinumab
Also written as “Secukinumab”, “AIN457” and “Secukinumab 300 mg”.
Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Spondylitis, Ankylosing · Arthritis, Rheumatoid · Hidradenitis Suppurativa, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 1254 open or running | phase 4since Jul 12, 2015 | Dec 21, 2007 | Feb 8, 2028phase 4 · NCT05622708 |
| Taizhou Mabtech Pharmaceutical | 20 open or running | phase 1since Jan 29, 2023 | Jan 29, 2023 | none ahead |
| Johnson & Johnson | 10 open or running | phase 1since Oct 13, 2020 | Oct 13, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Feb 25, 2015.
- Jun 15, 2021Phase 3 study in Giant Cell ArteritisNovartis · NCT04930094 · 354 enrolled · United States, Argentina, Australia and more
- Jan 12, 20222 phase 3 studiesNovartis · NCT05206591, NCT05232864
- Feb 22, 2022Phase 3 study in Giant Cell ArteritisNovartis · NCT05380453 · 151 enrolled · Germany
- Oct 4, 2022Phase 3 study in TendinopathyNovartis · NCT05569174 · 62 enrolled · Germany
- Nov 9, 2022Phase 4 study in Non-Radiographic Axial SpondyloarthritisNovartis · NCT05622708 · 240 enrolled · Belgium, Brazil, Colombia and more
- Jan 27, 2023Phase 3 study in Rotator Cuff TendinopathyNovartis · NCT05722522 · 33 enrolled · United States, Argentina, Bulgaria and more
- Jan 29, 2023Taizhou Mabtech Pharmaceutical's first study: phase 1 study in PsoriasisNew to Taizhou Mabtech PharmaceuticalTaizhou Mabtech Pharmaceutical · NCT05734482 · 130 enrolled · China
- Feb 1, 2023Phase 3 study in Rotator Cuff TendinopathyNovartis · NCT05758415 · 60 enrolled · United States, China, Italy and more
- Mar 6, 2023Phase 3 study in Polymyalgia RheumaticaNovartis · NCT05767034 · 381 enrolled · United States, Argentina, Australia and more
- Nov 8, 2023Phase 1 study in Giant Cell ArteritisNovartis · NCT06130540 · 65 enrolled · United States, Czechia, Italy and more
- Mar 20, 2024Phase 3 study in Polymyalgia RheumaticaNovartis · NCT06331312 · 162 enrolled · United States, Argentina, Australia and more
- Dec 20, 2024Phase 1 study in Arthritis, JuvenileNovartis · NCT06751238 · 20 planned · United States
- Nov 19, 2025Phase 1 study in PsoriasisTaizhou Mabtech Pharmaceutical · NCT07254325 · 114 enrolled · China
- Mar 18, 2026Phase 4 study in Hidradenitis SuppurativaNovartis · NCT07489573 · 36 planned · China
Ahead
- Feb 8, 2028Primary completion: phase 4 study in Non-Radiographic Axial SpondyloarthritisNovartis · NCT05622708
- May 8, 2028Primary completion: phase 3 study in Polymyalgia RheumaticaNovartis · NCT06331312
- Sep 25, 2029Primary completion: phase 4 study in Hidradenitis SuppurativaNovartis · NCT07489573
- Oct 31, 2029Primary completion: phase 1 study in Arthritis, JuvenileNovartis · NCT06751238
TargetBeta
“A recombinant human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin 17A (IL-17A; IL-17), ”NCIt, by rule
“Interleukin 17A inhibitor”ChEMBL 37, by rule
Other programs on IL17A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ixekizumabrule | Eli Lilly | phase 4 | 38 |
| vunakizumabrule | Jiangsu HengRui Medicine | phase 4 | 17 |
| bimekizumabrule | UCB | phase 3 | 43 |
| sonelokimabrule | moonlake-immunotherapeutics-ag | phase 3 | 12 |
| tibulizumabrule | Eli Lilly | phase 2 | 5 |
| SCT650Crule | Sinocelltech Group | phase 2 | 3 |
| UA026rule | usynova-pharmaceuticals-ltd | phase 1 | 1 |
Studies
The newest 60 of 128 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07489573Hidradenitis Suppurativa · China | 4 | Recruiting | Novartis | Sep 25, 2029 | 36 |
| NCT07254325Psoriasis · China | 1 | Completed | Taizhou Mabtech Pharmaceutical | Jun 12, 2026 | 114 |
| NCT06751238Arthritis, Juvenile · United States | 1 | Recruiting | Novartis | Oct 31, 2029 | 20 |
| NCT06331312Polymyalgia Rheumatica · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novartis | May 8, 2028 | 162 |
| NCT06130540Giant Cell Arteritis · United States, Czechia, Italy and more | 1 | Completed | Novartis | Mar 12, 2025 | 65 |
| NCT05767034Polymyalgia Rheumatica · United States, Argentina, Australia and more | 3 | Completed | Novartis | Sep 10, 2025 | 381 |
| NCT05758415Rotator Cuff Tendinopathy · United States, China, Italy and more | 3 | Terminated | Novartis | Oct 17, 2024 | 60 |
| NCT05734482Psoriasis · China | 1 | Completed | Taizhou Mabtech Pharmaceutical | Jul 3, 2023 | 130 |
| NCT05722522Rotator Cuff Tendinopathy · United States, Argentina, Bulgaria and more | 3 | Terminated | Novartis | Oct 17, 2024 | 33 |
| NCT05622708Non-Radiographic Axial Spondyloarthritis · Belgium, Brazil, Colombia and more | 4 | Active, not recruiting | Novartis | Feb 8, 2028 | 240 |
| NCT05569174Tendinopathy · Germany | 3 | Completed | Novartis | Dec 18, 2024 | 62 |
| NCT05380453Giant Cell Arteritis · Germany | 3 | Completed | Novartis | Feb 24, 2026 | 151 |
| NCT05232864Lupus Nephritis · Australia, Brazil, Colombia and more | 3 | Terminated | Novartis | Aug 23, 2023 | 31 |
| NCT05206591Active Peripheral Spondyloarthritis (pSpA) | 3 | Withdrawn | Novartis | Mar 20, 2028 | 0 |
| NCT04930094Giant Cell Arteritis · United States, Argentina, Australia and more | 3 | Completed | Novartis | Apr 11, 2025 | 354 |
| NCT04732117Non-Radiographic Axial Spondyloarthritis · China | 3 | Completed | Novartis | Apr 3, 2024 | 137 |
| NCT04711902Arthritis, Psoriatic · China | 3 | Completed | Novartis | Jun 2, 2022 | 41 |
| NCT04737330Graves Ophthalmopathy · Germany | 3 | Terminated | Novartis | May 16, 2023 | 28 |
| NCT04632927Arthritis, Psoriatic · Germany | 3 | Completed | Novartis | Oct 22, 2024 | 119 |
| NCT04589026Healthy · Belgium | 1 | Completed | Johnson & Johnson | May 6, 2021 | 12 |
| NCT04488185Psoriasis | 4 | Withdrawn | Novartis | Mar 24, 2021 | 0 |
| NCT04237116Non-alcoholic Fatty Liver Disease · Germany, Spain | 3 | Terminated | Novartis | Jun 29, 2021 | 10 |
| NCT04300296Lichen Planus · United States, France, Germany | 2 | Completed | Novartis | Nov 16, 2021 | 111 |
| NCT04181762Lupus Nephritis · United States, Argentina, Australia and more | 3 | Terminated | Novartis | Sep 13, 2023 | 275 |
| NCT04179175Hidradenitis Suppurativa · United States, Argentina, Australia and more | 3 | Completed | Novartis | May 26, 2023 | 702 |
| NCT04209205Arthritis, Psoriatic · United States, Brazil, Bulgaria and more | 3 | Completed | Novartis | May 17, 2022 | 381 |
| NCT04156620Spondylitis, Ankylosing · United States, Belgium, Brazil and more | 3 | Completed | Novartis | Feb 17, 2022 | 527 |
| NCT03765788Giant Cell Arteritis · Germany | 2 | Completed | Novartis | Jun 8, 2021 | 52 |
| NCT03769168Arthritis, Juvenile · United States, Belgium, Germany and more | 3 | Completed | Novartis | Nov 7, 2024 | 55 |
| NCT03713632Hidradenitis Suppurativa · United States, Argentina, Belgium and more | 3 | Completed | Novartis | Sep 23, 2021 | 545 |
| NCT03713619Hidradenitis Suppurativa · United States, Argentina, Australia and more | 3 | Completed | Novartis | Oct 1, 2021 | 544 |
| NCT03668613Skin Diseases · United States, Belgium, Czechia and more | 3 | Completed | Novartis | Sep 19, 2019 | 84 |
| NCT03589885Plaque Psoriasis · United States, Canada, Germany and more | 3 | Completed | Novartis | Nov 19, 2019 | 122 |
| NCT03504852Psoriasis · United States, Canada, Czechia and more | 3 | Completed | Novartis | Sep 13, 2019 | 331 |
| NCT03344640Tendinopathy · United States, Czechia, Germany and more | 2 | Completed | Novartis | Aug 2, 2019 | 96 |
| NCT03350815Spondylitis, Ankylosing · United States | 4 | Completed | Novartis | Mar 11, 2021 | 322 |
| NCT03259074Spondylitis, Ankylosing · United States, Argentina, Australia and more | 3 | Completed | Novartis | Nov 12, 2021 | 859 |
| NCT03136861Spondylarthritis · Belgium, Bulgaria, Croatia and more | 3 | Completed | Novartis | Feb 15, 2019 | 383 |
| NCT03066609Skin Diseases · China, Hungary, Malaysia and more | 3 | Completed | Novartis | Dec 21, 2017 | 543 |
| NCT03055494Psoriasis · United States | 4 | Completed | Novartis | Apr 25, 2018 | 102 |
| NCT03031782Arthritis, Juvenile · United States, Belgium, Germany and more | 3 | Completed | Novartis | Oct 7, 2020 | 86 |
| NCT03020199Psoriasis · Argentina, Bulgaria, Canada and more | 4 | Completed | Novartis | Nov 30, 2021 | 196 |
| NCT02798211Arthritis, Psoriatic · United States, Puerto Rico | 4 | Completed | Novartis | Dec 5, 2018 | 258 |
| NCT02896127Spondylitis, Ankylosing · China, Czechia, Korea, Republic of and more | 3 | Completed | Novartis | May 14, 2018 | 458 |
| NCT02763046Spondylitis, Ankylosing · Germany | 4 | Completed | Novartis | Sep 24, 2019 | 211 |
| NCT02750592Spondylitis, Ankylosing · Japan | 3 | Completed | Novartis | Jul 5, 2017 | 30 |
| NCT02745080Arthritis, Psoriatic · United States, Australia, Bulgaria and more | 3 | Completed | Novartis | Dec 30, 2019 | 853 |
| NCT02771210Arthritis, Psoriatic · Bulgaria, Czechia, Germany and more | 3 | Completed | Novartis | Dec 11, 2019 | 204 |
| NCT02721966Arthritis, Psoriatic · Belgium, Bulgaria, Czechia and more | 3 | Completed | Novartis | Jun 26, 2019 | 503 |
| NCT02748863Psoriasis · United States, Belgium, Canada and more | 3 | Completed | Novartis | Aug 8, 2017 | 214 |
| NCT02690701Psoriasis · United States | 4 | Completed | Novartis | Apr 26, 2017 | 91 |
| NCT02752776Plaque, Amyloid · Belgium, Bulgaria, Czechia and more | 4 | Completed | Novartis | Mar 28, 2018 | 1,660 |
| NCT02662985Arthritis, Psoriatic · United States, Argentina, Austria and more | 3 | Completed | Novartis | Nov 10, 2020 | 166 |
| NCT02826603Plaque Psoriasis · United States, Canada, Czechia and more | 3 | Completed | Novartis | Jul 9, 2018 | 1,114 |
| NCT02607774Moderate to Severe Plaque Psoriasis · United States | 1 | Completed | Novartis | Dec 20, 2016 | 25 |
| NCT02696031Axial Spondyloarthritis · United States, Australia, Austria and more | 3 | Completed | Novartis | Jul 1, 2019 | 555 |
| NCT02559622Psoriasis · Germany | 3 | Completed | Novartis | Apr 2016 | 151 |
| NCT02547714Plaque Psoriasis · Japan | 4 | Completed | Novartis | May 2, 2016 | 34 |
| NCT02474082Psoriasis · Germany | 3 | Completed | Novartis | Jun 2016 | 202 |
| NCT02595970Psoriasis · France | 3 | Completed | Novartis | Feb 9, 2017 | 120 |
How it is read
Names in the registry
- “Secukinumab”, 47 entries
- “AIN457”, 38 entries
- “secukinumab”, 7 entries
- “Secukinumab 300 mg”, 6 entries
- “Secukinumab (AIN457)”, 6 entries
Conditions, from the studies’ own filings
- Psoriasis, 39 studies
- Arthritis, Psoriatic, 16 studies
- Spondylitis, Ankylosing, 13 studies
- Arthritis, Rheumatoid, 7 studies
- Hidradenitis Suppurativa, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.